ArticleBMC women's health2025
Survival analysis of borderline ovarian tumors: a 23-year retrospective study in a Middle Eastern cohort.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorderline ovarian tumors (BOTs) constitute a category of non-invasive epithelial neoplasms of the ovary, characterized by a substantially more favorable prognosis in comparison to their invasive malignant counterparts. Given their prevalence among young women, balancing oncologic safety with fertility preservation is critical for clinical management. This study evaluates factors associated with survival in patients with BOTs over a long-term follow-up period. MATERIALS AND
methodsThis retrospective cohort study examined data from 135 patients diagnosed with borderline ovarian tumors (BOTs) between January 2000 and December 2023 at medical centers associated with Urmia University of Medical Sciences. Clinical and histopathological parameters were carefully extracted from both electronic and paper-based medical records. Overall survival rates were estimated using the Kaplan-Meier method, and intergroup comparisons were performed with the log-rank test.
resultsThe mean patient age was 39.5 years; with most cases diagnosed at FIGO stage I (94.1%). Conservative surgical management was performed in 65.2% of patients, while 34.8% underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH + BSO). Survival rates at 1, 3, 5, and 10 years were 100%, 99.2%, 98.3%, and 97.2%, respectively. No statistically significant differences in survival were observed based on age) p = 0.442(, tumor size (P = 0.752), bilaterality (P = 0.969), Histopathology (P = 0.069), FIGO stage (P = 0.746), or surgical approach (P = 0.199).
conclusionBorderline ovarian tumors (BOTs) typically manifest a benign clinical trajectory, with conservative surgical approaches demonstrating both safety and efficacy, especially in women of reproductive age. The absence of correlations between select histopathological characteristics and survival outcomes underscores the need to avoid unnecessary surgical procedures, thereby optimizing patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.